Skip to main content

Advertisement

Table 4 Adverse events occurring in ≥ 3% of patients in any treatment group

From: Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

  Number (%) of patients with adverse event
Adverse event Rosuvastatin (n = 233) Atorvastatin (n = 236)
Nasopharyngitis 23 (9.9) 19 (8.1)
Myalgia 13 (5.6) 7 (3.0)
Inadequately controlled diabetes mellitus 14 (6.0) 11 (4.6)
Constipation 9 (3.9) 6 (2.5)
Headache 6 (2.6) 7 (3.0)
Urinary tract infection 9 (3.9) 2 (0.9)
Arthralgia 1 (0.4) 9 (3.8)